Replimune Group, Inc. announced the FDA accelerated approval of TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for unresectable advanced cutaneous melanoma following PD-1 progression, with a commercial launch anticipated within 60 days. The company completed a $150 million equity financing to support the launch and its ongoing IGNYTE-3 confirmatory trial, bringing total cash resources to approximately $336 million. For the fiscal first quarter ended June 30, 2026, Replimune reported a net loss of $69.8 million, with R&D expenses at $49.3 million and SG&A expenses at $19.0 million. The company also appointed Michelle DiNapoli as Chief Commercial Officer effective August 18, 2026. Replimune Group, Inc. is a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies.
